Nation RL, et al. Colistin and Polymyxin B: Peas in a Pod or Chalk and Cheese? Clin Infect Dis. 2014:59(1):88‐94.
Akajagbor DS, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013 Nov;57(9):1300‐3
Kwa, A et al. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct;5(5): 811‐21
Kassamali Z et al. To B or not to B, that is the question: is it time to replace colistin with polymyxin B? Pharmacotherapy. 2015 Jan;35(1):17‐21.
Kaye KS. (2015, September). Parenteral Use of Colistin (and Polymyxin B) in North America. In J. Li (Chair), The Polymyxin Jigsaw: More pieces put in place. Presentation conducted at the meeting of Polymyxins 2015, San Diego, CA.
Gales AC, et al. Contemporary Assessment of Antimicrobial Susceptiblity Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines. J Clin Micirobiol 2001;39(1):183‐190.
Galani I, et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008:31(5):434‐439.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 33 rd ed. CLSI supplement M100. Wayne PA; Clinical and Laboratory Standards Institute; 2020.
Tsuji BT, et al. International Consensus Guidelines for the Optimal Use of Polymyxins. Pharmacotherapy. 2019 Jan;39(1):10-39.